18:00 , Jan 11, 2019 |  BC Week In Review  |  Company News

AbbVie records $4B impairment on Stemcentrx deal

As multiple companies were announcing new deals on the eve of J.P. Morgan Healthcare Conference, AbbVie Inc. (NYSE:ABBV) found itself acknowledging one of its biggest deals was a flop. The company said Jan. 4 it...
19:43 , Jan 6, 2019 |  BC Extra  |  Company News

AbbVie records $4B impairment on Stemcentrx deal

As multiple companies were announcing new deals on the eve of J.P. Morgan Healthcare Conference, AbbVie Inc. (NYSE:ABBV) found itself acknowledging one of its biggest deals was a flop. The company said Friday it will...
22:03 , Jan 4, 2019 |  BC Week In Review  |  Financial News

On heels of series C, Harpoon files for IPO

Less than two months after raising a $70 million series C round, Harpoon Therapeutics Inc. (South San Francisco, Calif.) filed on Dec. 27 to raise $86.3 million in an IPO on NASDAQ. Harpoon is developing...
23:06 , Dec 27, 2018 |  BC Extra  |  Financial News

On heels of series C, Harpoon files for IPO

Less than two months after raising a $70 million series C round, Harpoon Therapeutics Inc. (South San Francisco, Calif.) filed Thursday to raise $86.3 million in an IPO on NASDAQ. Harpoon is developing tri-specific T...
01:28 , Dec 7, 2018 |  BC Week In Review  |  Clinical News

AbbVie's Rova-T suffers another setback in SCLC

AbbVie Inc. (NYSE:ABBV) said on Dec. 5 that it will stop enrollment in the Phase III TAHOE trial of Rova-T rovalpituzumab tesirine as second-line treatment of advanced or metastatic small cell lung cancer after the...
23:42 , Dec 5, 2018 |  BC Extra  |  Clinical News

AbbVie's Rova-T suffers another setback in SCLC

AbbVie Inc. (NYSE:ABBV) said late Wednesday that it will stop enrollment in the Phase III TAHOE trial of Rova-T rovalpituzumab tesirine as second-line treatment of advanced or metastatic small cell lung cancer after the product...
02:56 , May 4, 2018 |  BC Innovations  |  Targets & Mechanisms

Solid hopes for T cell bispecifics

As next-generation T cell bispecifics hit the clinic, demonstrating efficacy in solid tumors could earn them a place in the immuno-oncology tool kit alongside CAR T cells and checkpoint inhibitors. T cell bispecific antibodies bring...